The pharmacokinetics of factor VIII and factor IX: methodology, pitfalls and applications

This article reviews the pharmacokinetics of exogenous factor VIII and factor IX in patients with haemophilia. It focuses on the methodology (and inherent pitfalls) of pharmacokinetic studies, then summarizes available pharmacokinetic data and finally discusses some applications of pharmacokinetics for optimization of prophylactic treatment of haemophilia and for comparison of coagulation factor concentrates.

[1]  M. Morfini,et al.  Comparison of the recovery and half‐life of a high‐purity factor IX concentrate with those of a factor IX complex concentrate. Factor IX Study Group , 1995, Transfusion.

[2]  G. Savidge,et al.  The successful removal of a bleeding intracranial tumour in a severe haemophiliac using an adjusted dose continuous infusion of monoclonal factor VIII , 1995, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[3]  C. Kasper.  In vivo recovery and early half‐life of infused factor VIII in haemophilia A , 1995, Haemophilia : the official journal of the World Federation of Hemophilia.

[4]  P. Giangrande,et al.  A cross‐over pharmacokinetic and thrombogenicity study of a prothrombin complex concentrate and a purified factor IX concentrate , 1994, British journal of haematology.

[5]  I. Nilsson,et al.  Potency and In Vivo Recovery of High Purity Factor VIII Concentrates , 1994, Thrombosis and Haemostasis.

[6]  J. Does,et al.  Development and Small‐Scale Production of a Severely Heated Factor VIII Concentrate , 1994, Vox sanguinis.

[7]  S. Lethagen,et al.  Biochemical and In Vivo Properties of High Purity Factor IX Concentrates , 1993, Thrombosis and Haemostasis.

[8]  E. Berntorp,et al.  Pharmacokinetic dosing in prophylactic treatment of hemophilia A , 1993, European journal of haematology.

[9]  S. Cinotti,et al.  Pharmacokinetics, thrombogenicity and safety of a double-treated prothrombin complex concentrate. , 1993, Thrombosis research.

[10]  H. Kingdon,et al.  A Note on the Calculation of Recovery for Factor VIII Infusions , 1993, Thrombosis and Haemostasis.

[11]  C. Kessler,et al.  Coagulation factor IX: Successful surgical experience with a purified factor IX concentrate , 1992, American journal of hematology.

[12]  H. Pettersson,et al.  Twenty‐five years' experience of prophylactic treatment in severe haemophilia A and B , 1992, Journal of internal medicine.

[13]  E. Berntorp,et al.  Pharmacokinetics of Factor VIII in Humans , 1992, Clinical pharmacokinetics.

[14]  U. Delvos,et al.  Pharmacokinetics of two pasteurized factor VIII concentrates by different and multicenter assays of factor VIII activity. , 1992, Thrombosis research.

[15]  P. Saidi,et al.  Purified factor IX using monoclonal immunoaffinity technique: clinical trials in hemophilia B and comparison to prothrombin complex concentrates , 1992 .

[16]  R. Miller,et al.  In Vivo Recovery and Survival of Monoclonal-Antibody-Purified Factor VIII Concentrates , 1991, Thrombosis and Haemostasis.

[17]  A. Bloom,et al.  The pharmacokinetics of recombinant factor VIII. The rFactor VIII Clinical Trial Group. , 1991, Seminars in hematology.

[18]  P. Mannucci,et al.  Comparative evaluation of the pharmacokinetics of three monoclonal factor VIII concentrates. , 1991, Thrombosis research.

[19]  P. Mannucci,et al.  Determination of pharmacokinetics of replacement factor VIII. , 1990, Seminars in hematology.

[20]  P. Saidi,et al.  Clinical experience of a new monoclonal antibody purified factor IX: half-life, recovery, and safety in patients with hemophilia B. , 1990, Seminars in hematology.

[21]  H. Kingdon,et al.  Assay discrepancies with highly purified factor VIII concentrates. , 1990, Haemostasis.

[22]  D. Brettler,et al.  Factor VIII:C concentrate purified from plasma using monoclonal antibodies: human studies. , 1989, Blood.

[23]  C. Kasper,et al.  The pharmacology of a new pasteurized antihemophilic factor concentrate derived from human blood plasma , 1989, Transfusion.

[24]  S. Cinotti,et al.  Evaluation of factor VIII pharmacokinetics in hemophilia‐A subjects undergoing surgery and description of a nomogram for dosing calculations , 1989, American journal of hematology.

[25]  A Messori,et al.  Clinical Pharmacokinetics of Factor VIII in Patients with Classic Haemophilia , 1987, Clinical pharmacokinetics.

[26]  S. Cinotti,et al.  Single‐dose pharmacokinetics of Factor IX evaluated by model‐independent methods , 1987, European journal of haematology.

[27]  E. Wenzel,et al.  Factor VIII: C (FVIII: C) Recovery and Half-Life After Infusion of Steam-Treated High Purity Factor VIII Concentrate in Severe Hemophilia A - Comparison of One-Stage Assay, Two-Stage Assay and a Chromogenic Substrate Assay , 1986, Thrombosis and Haemostasis.

[28]  A. Messori,et al.  Pharmacokinetics of a new heat-treated concentrate of factor VIII estimated by model-independent methods. , 1986, Thrombosis research.

[29]  A. Messori,et al.  Kinetic evaluation of four Factor VIII concentrates by model-independent methods. , 2009, Scandinavian journal of haematology.

[30]  R. Miller,et al.  Evaluation of two viral inactivation methods for the preparation of safer factor VIII and factor IX concentrates , 1985, Transfusion.

[31]  J. Luck,et al.  Hematologic management of hemophilia A for surgery. , 1985, JAMA.

[32]  K. Schumacher,et al.  Comparison of Factor VIII concentrates in non-bleeding patients. , 2009, Scandinavian journal of haematology. Supplementum.

[33]  H. Kjellman.  Calculations of factor VIII in vivo recovery and half-life. , 2009, Scandinavian journal of haematology. Supplementum.

[34]  A Messori,et al.  A Calculator Program for Individualizing Factor VIII Dosage , 1984, Drug intelligence & clinical pharmacy.

[35]  A Messori,et al.  INDIVIDUALIZATION OF FACTOR VIII DOSAGE , 1984, Journal of clinical and hospital pharmacy.

[36]  P. Das,et al.  Heparin Small Pool High Yield Purified Factor VIII: In Vivo Recovery and Half-Life of Routinely Produced Freeze-Dried Concentrate , 1984, Thrombosis and Haemostasis.

[37]  J. Allain.  Principles of in vivo recovery and survival studies. , 1984, Scandinavian journal of haematology. Supplementum.

[38]  A. Aronstam,et al.  Effect of height and weight on the in vivo recovery of transfused factor VIII C. , 1982, Journal of clinical pathology.

[39]  J. Lloyd,et al.  Successive Factor VIII Doses for a Haemophiliac Undergoing Major Surgery Calculated on a Microcomputer , 1982, Thrombosis and Haemostasis.

[40]  P. Jones,et al.  The 'in vivo' survival characteristics of factor VIII procoagulant antigen (VIII:C Ag) in haemophilia A subjects. , 1982, Thrombosis research.

[41]  J. Soulier,et al.  In vitro and in vivo Characterization of Factor VIII Preparations , 1980, Vox Sanguinis.

[42]  T. Kirkwood,et al.  In Vivo Recovery of Factor VIII: A Comparison of One-Stage and Two-Stage Assay Methods , 1979, Thrombosis and Haemostasis.

[43]  J Feldschuh,et al.  Prediction of the Normal Blood Volume: Relation of Blood Volume to Body Habitus , 1977, Circulation.

[44]  J. Levin,et al.  FACTOR IX LEVELS IN PATIENTS WITH HEMOPHILIA B (CHRISTMAS DISEASE) FOLLOWING TRANSFUSION WITH CONCENTRATES OF FACTOR IX OR FRESH FROZEN PLASMA (FFP) , 1977, Medicine.

[45]  J. A. Robinson,et al.  Treatment of hemophilia B with a new clotting-factor concentrate. , 1969, The New England journal of medicine.

[46]  Riek,et al.  Survival of ' 251 odine-Labeled Factor VIII in Normals and Patients with Classic Hemophilia , 2022 .